文献速递头颈部肿瘤放疗

复发转移性头颈癌患者免疫应答激活(CONFRONT Ib/II期试验):阿维鲁单抗、短程放疗与环磷酰胺的多模式免疫治疗

Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide.
PubMed 文献 · Clin Transl Radiat Oncol · 2018-08-13

CONFRONT是一项开放标签、多中心、单臂Ib/II期试验,入组既往接受过至少一线含铂、氟尿嘧啶和西妥昔单抗治疗的复发/转移性头颈癌患者,给予每日50 mg节拍环磷酰胺、阿维鲁单抗10 mg/kg每2周一次及第8天单次8 Gy放疗,旨在通过多层面攻击肿瘤微环境增强免疫原性而不增加免疫检查点抑制剂的安全性负担。

要点

  • 铂类耐药复发/转移性头颈癌的二线治疗是当前未满足的临床需求。
  • 方案设计通过放疗诱导自体疫苗接种效应、节拍环磷酰胺抑制CD4+CD25+FoxP3+调节性T细胞功能及阿维鲁单抗阻断PD-1-PD-L1轴三重机制逆转免疫逃逸。
  • 理论上前述联合治疗可能提高阿维鲁单抗活性而不增加其毒性谱,并附设延伸至全部患者人群的转化研究。

核心结论

  • 该研究旨在验证多层面攻击肿瘤微环境可增强复发/转移性头颈癌免疫原性而不加重免疫检查点抑制剂安全性负担的假设。

研究设计与样本

  • 开放标签、多中心、单臂Ib/II期试验,入组既往接受过至少一线含铂、氟尿嘧啶和西妥昔单抗治疗的复发/转移性头颈癌患者。

主要发现

  • 治疗方案为每日50 mg节拍环磷酰胺持续给药无停药间期,阿维鲁单抗10 mg/kg第1天及此后每2周一次直至进展,第8天单次8 Gy放疗。
  • 抗PD-1治疗可改善复发/转移性头颈癌患者的总生存和生活质量,与既往化疗线数无关,但长期生存者比例仍然有限。
  • 附设的转化研究将扩展至全部患者人群。

关键数值与推荐

  • 环磷酰胺:每日50 mg节拍剂量,无停药间期。
  • 阿维鲁单抗:10 mg/kg,第1天给药,此后每2周一次直至进展。
  • 放疗:第8天单次8 Gy。
  • 入组条件:既往至少接受过一线含铂、氟尿嘧啶和西妥昔单抗的治疗。
  • 试验注册号:EudraCT 2017-000353-39。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION AND BACKGROUND: Second-line treatment of platinum-resistant relapsed/metastatic (R/M) head and neck cancer (HNC) is a currently unmet clinical need. Clinical trials showed improvement in overall survival and quality of life of R/M-HNC patients treated with anti-PD-1 regardless of the number of prior chemotherapy lines; however, the percentage of long-term survivors remains limited.This study aims to test the hypothesis that attacking the tumor microenvironment at multiple levels can increase immunogenicity of R/M-HNC without worsening the safety profile of immune checkpoint inhibitors. METHODS/DESIGN: In this open label, multi-center, single-arm, Phase Ib/II, R/M-HNC patients pretreated with at least one line of therapy containing platinum, fluorouracil, and cetuximab will receive a daily metronomic dose of 50 mg cyclophosphamide without a drug-free break, 10 mg/kg avelumab on day 1 and every other week until progression, and a single fraction of 8 Gy radiotherapy on day 8. DISCUSSION: The treatment protocol aims to reverse immune evasion of the tumor through a radiotherapy-induced self-vaccination effect, suppression of CD4+ CD25+ FoxP3+ regulatory T-cell function by metronomic cyclophosphamide, and effector T-cell reactivation owing to the inhibition of the PD-1-PD-L1 axis by avelumab.The immunologic interplay induced by the proposed combined treatment may theoretically improve the activity of avelumab without increasing its toxicity profile.Finally, an ancillary translational study will be extended to all the patients' population. TRIAL REGISTRATION: EudraCT n. 2017-000353-39.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Merlano MC, Merlotti AM, Licitra L, et al. Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. Clin Transl Radiat Oncol. 2018. PMID: 30186977. doi:10.1016/j.ctro.2018.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。